Protocols
|
June 13, 2023

A Functional Medicine Intestinal Methanogen Overgrowth Protocol (IMO): Testing, Nutrition, and Supplements

Medically Reviewed by
Updated On
September 17, 2024

What if there were a solution to the chronic discomfort of constipation, bloating, and abdominal pain that plagues those diagnosed with irritable bowel syndrome with constipation (IBS-C)? For many patients, these symptoms are a persistent challenge, leading to frustration and a diminished quality of life.

However, emerging research suggests that a significant subset of IBS-C sufferers may be dealing with a condition known as intestinal methanogen overgrowth. This discovery opens the door to targeted treatments that go beyond managing symptoms to potentially offering a curative approach. 

By accurately diagnosing and treating IMO, healthcare providers can tailor interventions that address the root cause, bringing countless individuals lasting relief and a renewed sense of digestive freedom.

[signup]

What Is Intestinal Methanogen Overgrowth?

Intestinal methanogen overgrowth, or IMO, occurs when methane-producing archaea are found in excess numbers at any point along the digestive tract. Overgrowth of these bacteria-like microorganisms, predominantly Methanobrevibacter smithii, can cause digestive symptoms that often go undiagnosed or misdiagnosed as IBS-C.

IMO is a newer term that replaced methane-dominant SIBO (small intestinal bacterial overgrowth) to characterize the overgrowth of methanogens anywhere along the digestive tract. This newer terminology distinguishes two main differences between IMO and SIBO:

  1. Methanogens called archaea, not bacteria, are responsible for causing IMO.
  2. IMO can occur anywhere along the length of the digestive tract

Intestinal Methanogen Overgrowth Signs & Symptoms

IBS, SIBO, and IMO share many of the same symptoms, including:

  • Abdominal pain
  • Bloating and abdominal distension
  • Gas
  • Nausea
  • Constipation and diarrhea
  • Indigestion and heartburn

Distinct gut microtypes are linked to breath-gas patterns in patients with IBS-C. Driven by methanogens, such as M. smithii, methane gas has been shown to slow intestinal transit directly, causing constipation and strongly linking it to IBS-C. This differs from the other subtypes of SIBO (hydrogen- and hydrogen sulfide-predominant SIBO), which are more often associated with diarrheal presentations.

Malabsorption can result from IMO, causing unintentional weight loss, fatigue, and fatty stools. Deficiencies in iron and vitamins B12 and D are also commonly measured on labs. (12)

Extraintestinal symptoms are also common in the context of IMO, such as headaches, joint pain, brain fog, skin lesions, and changes in mood (12).

Root Causes of Intestinal Methanogen Overgrowth

A breakdown in the innate protective mechanisms against archaeal overgrowth predisposes an individual to IMO. Interruptions in normal digestive enzyme production, intestinal motility, and secretory IgA can cause IMO. (12)

Food poisoning increases the risk of IBS by four times, and it is estimated that 80% of patients with IBS have at least one of the three SIBO subtypes. When you get food poisoning, the body produces antibodies that attack the interstitial cells of Cajal, which help with intestinal motility. This disrupts the migrating motor complex (MMC), a vital housekeeping function that essentially acts to sweep out the bowels. An impaired MMC increases the risk for methanogens to overgrow in the intestines. (28)

Advanced age, abdominal surgery, intestinal anatomic variations, and chronic stress can interfere with normal gastrointestinal function and increase the risk of IMO (12).

Medical conditions that reduce mucosal immunity, slow intestinal motility, and create intestinal adhesions can contribute to methanogenic overgrowth. These may include diabetes mellitus, hypothyroidism, autoimmune diseases, colon cancer, and inflammatory bowel disease (IBD). (11, 12, 14)

The use of certain medications can also increase IMO risk. Chronic, frequent use of antibiotics can disrupt the normal balance of beneficial bacteria, allowing the opportunity for methanogens to overgrow. Opiates and smooth muscle relaxants contribute to dysmotility. Proton pump inhibitors and other acid-reducing medications reduce hydrochloric acid, a natural antimicrobial digestive secretion. (11, 12, 14)

How to Diagnose Intestinal Methanogen Overgrowth

Doctors can diagnose IMO and uncover its underlying causes using a step-wise approach.

Step 1: Breath Test

A SIBO/IMO lactulose breath test is an at-home test that measures gaseous byproducts of bacterial and methanogenic fermentation exhaled through the lungs. Due to cost and convenience, this is the most common test utilized in clinical practice to diagnose IMO. According to the North American Consensus guidelines, a methane peak of at least 10 ppm at any time point during the test is diagnostic of IMO.

Any one of these three breath tests can diagnose IMO: 

Step 2: Tests to Investigate the Root Cause of IMO

Once a patient is diagnosed with IMO, a common question arises: "Why?" The following tests can help uncover IMO's underlying causes.

Vinculin & CdtB Antibodies

In addition to a positive SIBO breath test, positive vinculin and CdtB antibodies confirm a diagnosis of post-infectious IBS and food poisoning as the cause of IMO. The ibs-smart panel by Gemelli Biotech measures both of these antibodies.

Thyroid Panel

A comprehensive thyroid panel screens for hypothyroidism and thyroid autoimmunity, which can impair digestive enzyme secretions and intestinal motility. 

Examples of comprehensive thyroid panels that include TSH, free T3, free T4, and thyroid antibodies include: 

Hemoglobin A1c (HbA1c)

HbA1c is a three-month average blood sugar diagnostic for diabetes. In advanced and untreated diabetes, damage to the nerves that innervate the intestines can cause gastroparesis (slowed stomach emptying) and impaired intestinal motility.

Imaging

Some patients may require endoscopy, colonoscopy, barium follow-through, and/or antroduodenal manometry to confirm inflammatory bowel disorders, intestinal structural anomalies, and MMC deficiencies.

Step 3: Tests to Customize IMO Treatment Plan

Additional functional medicine tests can help individualize treatment plans. Although these tests may not be indicated for every individual, they are commonly recommended by providers during a comprehensive gastrointestinal evaluation.

Comprehensive Stool Test

A comprehensive stool test cannot diagnose IMO, but it can detect digestive enzyme deficiencies, intestinal inflammation, and large intestinal dysbiotic patterns that contribute to or result from its presence.

These are popular comprehensive stool tests ordered through Rupa Health:

Food Sensitivities

When present in the small intestine, IMO causes inflammation and a leaky gut. Increased intestinal permeability increases the risk of food sensitivities, which exacerbate mealtime digestive symptoms. 

Any of these food sensitivity panels can help personalize a therapeutic dietary plan for patients with significant food-related symptoms while IMO is being treated:

Cortisol Testing

A salivary cortisol test identifies maladaptive adrenal stress responses that can occur with chronic stress. Cortisol secretion imbalances can impair gastrointestinal digestive secretions and motility and often present as physical and mental fatigue and insomnia, further perpetuating the maladaptive stress cycle.

When trying to assess the stress response, any one of these panels is an excellent place to start:

[signup]

Treatment Plan for Intestinal Methanogen Overgrowth

A successful treatment plan for IMO can be divided into three stages.

Step 1: Antimicrobial Therapy

Here's Why This Is Important:

The use of antibiotics is the cornerstone of IMO treatment. The goal is to reduce the intestinal methanogen population, which is directly responsible for causing the symptoms associated with this condition.

How Do You Do This?

Prescription or herbal antibiotics effectively treat methanogen overgrowth in the gastrointestinal tract.

A standard course of antibiotic therapy involves two weeks of rifaximin with either neomycin or metronidazole. Multiple courses may be required for complete eradication. (33

Herbal therapy is equally as effective as rifaximin for treating SIBO. A course of herbal antimicrobial treatment for IMO involves dosing two herbs together for six weeks. Dosing more than two herbs at once does not usually provide additional benefits. As with prescription antibiotics, multiple courses may be required for complete IMO eradication. Combinations of the following botanical products can be considered for herbal IMO eradication protocols: 

The elemental diet (ED) is the only current diet with data supporting its ability to eradicate SIBO/IMO. The ED is the most effective treatment option for SIBO and IMO, with an 80% eradication rate after two weeks of treatment. However, the ED is unpalatable to most, and commercial formulas are expensive. Additionally, as it is a liquid-only diet, many experience emotional challenges during the treatment protocol. Patients can make their elemental formula at home or buy commercially made formulas. (13)

Step 2: Palliate Symptoms

Here's Why This Is Important:

Many patients with IMO experience digestive symptoms related to mealtimes, as methanogens ferment dietary carbohydrates, resulting in increased methane production and associated symptoms like gas, bloating, abdominal pain, and constipation. 

How Do You Do This?

Nutritional modifications that limit fermentable carbohydrates can be helpful in palliating digestive symptoms but are usually not effective on their own in IMO eradication. Therapeutic elimination diets used for symptom relief during IMO treatment include the low FODMAP, Specific Carbohydrate (SCD), Bi-Phasic, GAPS, and Cedars-Sinai diets. (13)

In addition, a prokinetic agent can be added to either herbal or pharmaceutical antimicrobial therapy to support intestinal motility. Prokinetics can assist in relieving gas and bloating symptoms. Ginger, for example, is a popular natural prokinetic that has been shown to stimulate gastric emptying when administered to patients in a dose of 1.2 grams.

Step 3: Prevention

Why Is This Important?

Approximately 45% of patients experience recurrent IMO after completing antibiotic therapy. Implementing strategies to prevent recurrence can help reduce the likelihood of rapid IMO relapse.

How Do You Do This?

IMO should be viewed as a symptom of another gastrointestinal imbalance. If the root cause of IMO is ignored, it will likely recur after antibiotic therapy. Given the complexity of IMO pathogenesis, this article cannot outline specific treatment protocols for every possible underlying cause of IMO. Using patient history and specialty labs can help determine likely causes of IMO. Check out the Rupa Health Magazine for more articles on integrative treatment strategies and protocols relevant to your patient's case.

The Risks of Untreated Intestinal Methanogen Overgrowth

The persistent overgrowth of methanogenic archaea leads to continuous methane production in the gut. Elevated methane levels are closely associated with chronic gastrointestinal symptoms that can significantly impair a patient's quality of life.

Chronic constipation can lead to complications such as hemorrhoids, anal fissures, and rectal prolapse due to prolonged straining. 

Untreated IMO can exacerbate or contribute to the development of other functional gastrointestinal disorders, such as IBS or leaky gut syndrome. Once leaky gut has developed, toxins and undigested food particles can enter the bloodstream, potentially triggering systemic immune responses and inflammation linked to various conditions, including metabolic disorders, autoimmune diseases, rosacea, restless legs syndrome, and interstitial cystitis.

[signup]

Key Takeaways:

  • Intestinal methanogen overgrowth is a common digestive problem often misdiagnosed as IBS-C. Diagnosing and treating IMO helps provide long-term solutions for otherwise chronic and untreatable digestive symptoms. 
  • IMO treatment can be complex, given the many factors contributing to its development. Working with a trained medicine provider who is knowledgeable about proper root-cause treatment approaches, long-term eradication and prevention of IMO is possible.

What if there were a way to help manage the chronic discomfort of constipation, bloating, and abdominal pain that affects those diagnosed with irritable bowel syndrome with constipation (IBS-C)? For many individuals, these symptoms are a persistent challenge, leading to frustration and a diminished quality of life.

However, emerging research suggests that a significant subset of IBS-C sufferers may be dealing with a condition known as intestinal methanogen overgrowth. This discovery opens the door to targeted approaches that go beyond managing symptoms to potentially offering a more focused intervention. 

By accurately identifying and addressing IMO, healthcare providers can tailor interventions that may help manage the underlying factors, bringing countless individuals potential relief and a renewed sense of digestive well-being.

[signup]

What Is Intestinal Methanogen Overgrowth?

Intestinal methanogen overgrowth, or IMO, occurs when methane-producing archaea are found in excess numbers at any point along the digestive tract. Overgrowth of these bacteria-like microorganisms, predominantly Methanobrevibacter smithii, can cause digestive symptoms that often go undiagnosed or misdiagnosed as IBS-C.

IMO is a newer term that replaced methane-dominant SIBO (small intestinal bacterial overgrowth) to characterize the overgrowth of methanogens anywhere along the digestive tract. This newer terminology distinguishes two main differences between IMO and SIBO:

  1. Methanogens called archaea, not bacteria, are responsible for causing IMO.
  2. IMO can occur anywhere along the length of the digestive tract

Intestinal Methanogen Overgrowth Signs & Symptoms

IBS, SIBO, and IMO share many of the same symptoms, including:

  • Abdominal pain
  • Bloating and abdominal distension
  • Gas
  • Nausea
  • Constipation and diarrhea
  • Indigestion and heartburn

Distinct gut microtypes are linked to breath-gas patterns in patients with IBS-C. Driven by methanogens, such as M. smithii, methane gas has been shown to slow intestinal transit directly, which may contribute to constipation and is strongly linked to IBS-C. This differs from the other subtypes of SIBO (hydrogen- and hydrogen sulfide-predominant SIBO), which are more often associated with diarrheal presentations.

Malabsorption can result from IMO, potentially causing unintentional weight loss, fatigue, and fatty stools. Deficiencies in iron and vitamins B12 and D are also commonly measured on labs. (12)

Extraintestinal symptoms are also common in the context of IMO, such as headaches, joint pain, brain fog, skin lesions, and changes in mood (12).

Root Causes of Intestinal Methanogen Overgrowth

A breakdown in the innate protective mechanisms against archaeal overgrowth may predispose an individual to IMO. Interruptions in normal digestive enzyme production, intestinal motility, and secretory IgA can contribute to IMO. (12)

Food poisoning increases the risk of IBS by four times, and it is estimated that 80% of patients with IBS have at least one of the three SIBO subtypes. When you get food poisoning, the body produces antibodies that may affect the interstitial cells of Cajal, which help with intestinal motility. This disrupts the migrating motor complex (MMC), a vital housekeeping function that essentially acts to sweep out the bowels. An impaired MMC increases the risk for methanogens to overgrow in the intestines. (28)

Advanced age, abdominal surgery, intestinal anatomic variations, and chronic stress can interfere with normal gastrointestinal function and may increase the risk of IMO (12).

Medical conditions that reduce mucosal immunity, slow intestinal motility, and create intestinal adhesions can contribute to methanogenic overgrowth. These may include diabetes mellitus, hypothyroidism, autoimmune diseases, colon cancer, and inflammatory bowel disease (IBD). (11, 12, 14)

The use of certain medications can also increase IMO risk. Chronic, frequent use of antibiotics can disrupt the normal balance of beneficial bacteria, allowing the opportunity for methanogens to overgrow. Opiates and smooth muscle relaxants may contribute to dysmotility. Proton pump inhibitors and other acid-reducing medications reduce hydrochloric acid, a natural antimicrobial digestive secretion. (11, 12, 14)

How to Diagnose Intestinal Methanogen Overgrowth

Doctors can diagnose IMO and uncover its underlying factors using a step-wise approach.

Step 1: Breath Test

A SIBO/IMO lactulose breath test is an at-home test that measures gaseous byproducts of bacterial and methanogenic fermentation exhaled through the lungs. Due to cost and convenience, this is the most common test utilized in clinical practice to diagnose IMO. According to the North American Consensus guidelines, a methane peak of at least 10 ppm at any time point during the test is indicative of IMO.

Any one of these three breath tests can help identify IMO: 

Step 2: Tests to Investigate the Root Cause of IMO

Once a patient is identified with IMO, a common question arises: "Why?" The following tests can help uncover IMO's underlying factors.

Vinculin & CdtB Antibodies

In addition to a positive SIBO breath test, positive vinculin and CdtB antibodies may suggest a diagnosis of post-infectious IBS and food poisoning as the cause of IMO. The ibs-smart panel by Gemelli Biotech measures both of these antibodies.

Thyroid Panel

A comprehensive thyroid panel screens for hypothyroidism and thyroid autoimmunity, which can impair digestive enzyme secretions and intestinal motility. 

Examples of comprehensive thyroid panels that include TSH, free T3, free T4, and thyroid antibodies include: 

Hemoglobin A1c (HbA1c)

HbA1c is a three-month average blood sugar diagnostic for diabetes. In advanced and untreated diabetes, damage to the nerves that innervate the intestines can cause gastroparesis (slowed stomach emptying) and impaired intestinal motility.

Imaging

Some patients may require endoscopy, colonoscopy, barium follow-through, and/or antroduodenal manometry to confirm inflammatory bowel disorders, intestinal structural anomalies, and MMC deficiencies.

Step 3: Tests to Customize IMO Management Plan

Additional functional medicine tests can help individualize management plans. Although these tests may not be indicated for every individual, they are commonly recommended by providers during a comprehensive gastrointestinal evaluation.

Comprehensive Stool Test

A comprehensive stool test cannot diagnose IMO, but it can detect digestive enzyme deficiencies, intestinal inflammation, and large intestinal dysbiotic patterns that may contribute to or result from its presence.

These are popular comprehensive stool tests ordered through Rupa Health:

Food Sensitivities

When present in the small intestine, IMO may contribute to inflammation and a leaky gut. Increased intestinal permeability may increase the risk of food sensitivities, which can exacerbate mealtime digestive symptoms. 

Any of these food sensitivity panels can help personalize a therapeutic dietary plan for patients with significant food-related symptoms while IMO is being managed:

Cortisol Testing

A salivary cortisol test identifies maladaptive adrenal stress responses that can occur with chronic stress. Cortisol secretion imbalances can impair gastrointestinal digestive secretions and motility and often present as physical and mental fatigue and insomnia, further perpetuating the maladaptive stress cycle.

When trying to assess the stress response, any one of these panels is an excellent place to start:

[signup]

Management Plan for Intestinal Methanogen Overgrowth

A successful management plan for IMO can be divided into three stages.

Step 1: Antimicrobial Therapy

Here's Why This Is Important:

The use of antibiotics is a common approach in IMO management. The goal is to reduce the intestinal methanogen population, which may contribute to the symptoms associated with this condition.

How Do You Do This?

Prescription or herbal antibiotics are often used to help manage methanogen overgrowth in the gastrointestinal tract.

A standard course of antibiotic therapy involves two weeks of rifaximin with either neomycin or metronidazole. Multiple courses may be required for effective management. (33

Herbal therapy is considered effective for managing SIBO. A course of herbal antimicrobial treatment for IMO involves dosing two herbs together for six weeks. Dosing more than two herbs at once does not usually provide additional benefits. As with prescription antibiotics, multiple courses may be required for effective management. Combinations of the following botanical products can be considered for herbal IMO management protocols: 

The elemental diet (ED) is the only current diet with data supporting its ability to manage SIBO/IMO. The ED is considered an effective option for SIBO and IMO, with an 80% success rate after two weeks of treatment. However, the ED is unpalatable to most, and commercial formulas are expensive. Additionally, as it is a liquid-only diet, many experience emotional challenges during the treatment protocol. Patients can make their elemental formula at home or buy commercially made formulas. (13)

Step 2: Palliate Symptoms

Here's Why This Is Important:

Many patients with IMO experience digestive symptoms related to mealtimes, as methanogens ferment dietary carbohydrates, resulting in increased methane production and associated symptoms like gas, bloating, abdominal pain, and constipation. 

How Do You Do This?

Nutritional modifications that limit fermentable carbohydrates can be helpful in managing digestive symptoms but are usually not effective on their own in IMO management. Therapeutic elimination diets used for symptom relief during IMO management include the low FODMAP, Specific Carbohydrate (SCD), Bi-Phasic, GAPS, and Cedars-Sinai diets. (13)

In addition, a prokinetic agent can be added to either herbal or pharmaceutical antimicrobial therapy to support intestinal motility. Prokinetics can assist in relieving gas and bloating symptoms. Ginger, for example, is a popular natural prokinetic that has been shown to stimulate gastric emptying when administered to patients in a dose of 1.2 grams.

Step 3: Prevention

Why Is This Important?

Approximately 45% of patients experience recurrent IMO after completing antibiotic therapy. Implementing strategies to help prevent recurrence can help reduce the likelihood of rapid IMO relapse.

How Do You Do This?

IMO should be viewed as a symptom of another gastrointestinal imbalance. If the underlying factors of IMO are ignored, it may recur after antibiotic therapy. Given the complexity of IMO pathogenesis, this article cannot outline specific management protocols for every possible underlying factor of IMO. Using patient history and specialty labs can help determine likely factors of IMO. Check out the Rupa Health Magazine for more articles on integrative management strategies and protocols relevant to your patient's case.

The Risks of Untreated Intestinal Methanogen Overgrowth

The persistent overgrowth of methanogenic archaea leads to continuous methane production in the gut. Elevated methane levels are closely associated with chronic gastrointestinal symptoms that can significantly impair a patient's quality of life.

Chronic constipation can lead to complications such as hemorrhoids, anal fissures, and rectal prolapse due to prolonged straining. 

Untreated IMO can exacerbate or contribute to the development of other functional gastrointestinal disorders, such as IBS or leaky gut syndrome. Once leaky gut has developed, toxins and undigested food particles can enter the bloodstream, potentially triggering systemic immune responses and inflammation linked to various conditions, including metabolic disorders, autoimmune diseases, rosacea, restless legs syndrome, and interstitial cystitis.

[signup]

Key Takeaways:

  • Intestinal methanogen overgrowth is a common digestive problem often misdiagnosed as IBS-C. Identifying and managing IMO may help provide long-term solutions for otherwise chronic and challenging digestive symptoms. 
  • IMO management can be complex, given the many factors contributing to its development. Working with a trained healthcare provider who is knowledgeable about proper root-cause management approaches, long-term management and prevention of IMO is possible.
The information in this article is designed for educational purposes only and is not intended to be a substitute for informed medical advice or care. This information should not be used to diagnose or treat any health problems or illnesses without consulting a doctor. Consult with a health care practitioner before relying on any information in this article or on this website.

Learn more

No items found.

Lab Tests in This Article

  1. (SIBO) Small Intestinal Bacterial Overgrowth. Cleveland Clinic. Retrieved May 28, 2024, from https://my.clevelandclinic.org/health/diseases/21820-small-intestinal-bacterial-overgrowth-sibo#symptoms-and-causes
  2. Bertagna, B. (2024, March 5). The GAPS Diet: Principles, Therapeutic Uses, and Benefits. Rupa Health. https://www.rupahealth.com/post/the-gaps-diet-principles-therapeutic-uses-and-benefits
  3. Camilleri, M., & Atieh, J. (2021). New Developments in Prokinetic Therapy for Gastric Motility Disorders. Frontiers in Pharmacology, 12, 711500. https://doi.org/10.3389/fphar.2021.711500
  4. Chedid, V., Dhalla, S., Clarke, J. O., et al. (2014). Herbal Therapy is Equivalent to Rifaximin for the Treatment of Small Intestinal Bacterial Overgrowth. Global Advances in Health and Medicine, 3(3), 16–24. https://doi.org/10.7453/gahmj.2014.019
  5. Cloyd, J. (2022, December 8). Inflammatory Bowel Disease: Treatments for IBD Flares and Remission. Rupa Health. https://www.rupahealth.com/post/inflammatory-bowel-disease-ibd-treatments-for-flares-and-remission
  6. Cloyd, J. (2022, December 15). IBS-C: Diagnosis and Natural Treatments Options. Rupa Health. https://www.rupahealth.com/post/ibs-c-diagnosis-and-natural-treatments-options
  7. Cloyd, J. (2023, February 28). A Functional Medicine Protocol for Leaky Gut Syndrome. Rupa Health. https://www.rupahealth.com/post/a-functional-medicine-protocol-for-leaky-gut-syndrome
  8. Cloyd, J. (2023, March 1). How to Use The Elemental Diet in Clinic. Rupa Health. https://www.rupahealth.com/post/how-to-use-the-elemental-diet-in-clinic
  9. Cloyd, J. (2023, March 14). SIBO Testing 101: A Complete Guide to The Top 3 SIBO Tests. Rupa Health. https://www.rupahealth.com/post/sibo-testing-101-a-complete-guide-to-the-top-3-sibo-tests
  10. Cloyd, J. (2023, March 15). The relationship between the sleep stress cycle. Rupa Health. https://www.rupahealth.com/post/the-relationship-between-the-sleep-stress-cycle
  11. Cloyd, J. (2023, March 30). An In-Depth Overview of the Three Types of SIBO: Hydrogen, Methane, Hydrogen Sulfide. Rupa Health. https://www.rupahealth.com/post/an-in-depth-overview-of-the-three-types-of-sibo-hydrogen-methane-hydrogen-sulfide
  12. Cloyd, J. (2023, April 3). 5 Health Conditions That Are Associated with Small Intestinal Bacterial Overgrowth (SIBO). Rupa Health. https://www.rupahealth.com/post/5-health-conditions-that-are-associated-with-small-intestinal-bacterial-overgrowth-sibo
  13. Cloyd, J. (2023, April 26). Dietary Modifications for a Successful SIBO Treatment Plan. Rupa Health. https://www.rupahealth.com/post/dietary-modifications-for-a-successful-sibo-treatment-plan
  14. Cloyd, J. (2023, May 4). A Functional Medicine SIBO Protocol: Testing and Treatment. Rupa Health. https://www.rupahealth.com/post/a-functional-medicine-sibo-protocol
  15. Cloyd, J. (2023, June 22). The Cedars-Sinai Diet: A Comprehensive Guide for IBS and SIBO Patients. Rupa Health. https://www.rupahealth.com/post/the-cedars-sinai-diet-a-comprehensive-guide-for-ibs-and-sibo-patients
  16. Cloyd, J. (2023, June 23). Individualizing The SIBO Bi-Phasic Meal Plan With Specialty Labs. Rupa Health. https://www.rupahealth.com/post/individualizing-the-sibo-bi-phasic-meal-plan-with-specialty-labs
  17. Cloyd, J. (2023, November 16). How A Leaky Gut Could Be Contributing to Your Inflammation. Rupa Health. https://www.rupahealth.com/post/how-a-leaky-gut-could-be-contributing-to-your-inflammation
  18. Cloyd, J. (2023, December 26). How to Interpret An HbA1c Test and What it Means For Your Patient's Health. Rupa Health. https://www.rupahealth.com/post/how-to-interpret-an-hba1c-test-and-what-it-means-for-your-patients-health
  19. Cloyd, J. (2024, January 3). Saliva Testing: Cortisol and Hormone Test Result Interpretation Guide. Rupa Health. https://www.rupahealth.com/post/saliva-testing-cortisol-and-hormone-test-result-interpretation-guide
  20. Colonoscopy. Johns Hopkins Medicine. https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/colonoscopy
  21. Complications of Constipation. Stanford Medicine. https://stanfordhealthcare.org/medical-conditions/primary-care/constipation/complications.html
  22. DePorto, T. (2023, January 26). Using the Specific Carbohydrate Diet for IBD Symptom Relief. Rupa Health. https://www.rupahealth.com/post/using-the-specific-carbohydrate-diet-for-ibd-symptom-relief
  23. Effects of FODMAPs on the Gut. IFFGD. https://aboutibs.org/treatment/ibs-diet/low-fodmap-diet/effects-of-fodmaps-on-the-gut/
  24. Endoscopy. (2023, July 12). Cleveland Clinic. https://my.clevelandclinic.org/health/diagnostics/25126-endoscopy
  25. Ghoshal, U. C., Shukla, R., & Ghoshal, U. (2017). Small intestinal bacterial overgrowth and irritable bowel syndrome: A bridge between functional organic dichotomy. Gut and Liver, 11(2), 196–208.
  26. Greenan, S. (2021, November 18). How To Do A Low FODMAP Elimination Diet. Rupa Health. https://www.rupahealth.com/post/what-are-fodmaps
  27. Hu, M.-L., Rayner, C. K., Wu, K.-L., et al. (2011). Effect of ginger on gastric motility and symptoms of functional dyspepsia. World Journal of Gastroenterology, 17(1), 105–110. https://doi.org/10.3748/wjg.v17.i1.105
  28. Kim, J. H., Nam, S.-J., Park, S. C., et al. (2020). Association between interstitial cells of Cajal and anti-vinculin antibody in human stomach. The Korean Journal of Physiology & Pharmacology, 24(2), 185. https://doi.org/10.4196/kjpp.2020.24.2.185
  29. Klem, F., Wadhwa, A., Prokop, L. J., et al. (2017). Prevalence, Risk Factors, and Outcomes of Irritable Bowel Syndrome After Infectious Enteritis: A Systematic Review and Meta-analysis. Gastroenterology, 152(5), 1042-1054.e1. https://doi.org/10.1053/j.gastro.2016.12.039
  30. Ma, T., Chen, D.-D., Tu, Y., et al. (2016). Effect of supplementation of allicin on methanogenesis and ruminal microbial flora in Dorper crossbred ewes. J Anim Sci Biotechnol, 7(1). https://doi.org/10.1186/s40104-015-0057-5
  31. Maholy, N. (2023, March 9). Integrative Medicine Protocol For Reversing Type 2 Diabetes. Rupa Health. https://www.rupahealth.com/post/integrative-medicine-protocol-for-reversing-type-2-diabetes
  32. Patcharatrakul, T., & Gonlachanvit, S. (2013). Technique of Functional and Motility Test: How to Perform Antroduodenal Manometry. Journal of Neurogastroenterology and Motility, 19(3), 395–404. https://doi.org/10.5056/jnm.2013.19.3.395
  33. Pimentel, M., Saad, R. J., Long, M. D., et al. (2020). ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth. The American Journal of Gastroenterology, 115(2), 165–178. https://doi.org/10.14309/ajg.0000000000000501
  34. Rezaie, A., Buresi, M., Lembo, A., et al. (2017). Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus. The American Journal of Gastroenterology, 112(5), 775–784. https://doi.org/10.1038/ajg.2017.46
  35. Schor, J. (2014, March 24). Clinical Applications for Berberine. Natural Medicine Journal. https://www.naturalmedicinejournal.com/journal/clinical-applications-berberine
  36. Shahzad, H., Hussain, M. M., Abid, A., et al. (2021). Impact of Gastrointestinal Diseases on Health-Related Quality of Life of Patients in Pakistan. Cureus, 13(8). https://doi.org/10.7759/cureus.17374
  37. Si, W., Gong, J., Tsao, R., et al. (2006). Antimicrobial activity of essential oils and structurally related synthetic food additives towards selected pathogenic and beneficial gut bacteria. Journal of Applied Microbiology, 100(2), 296–305. https://doi.org/10.1111/j.1365-2672.2005.02789.x
  38. SIBO Causes, Symptoms, Diagnosis, & Treatment. Ibs-Smart. https://www.ibssmart.com/sibo-symptoms-and-diagnosis
  39. Small Bowel Follow-Through. Radiological Society of North America. https://www.radiologyinfo.org/en/info/small-bowel-follow-thru
  40. Sorathia, S. J., & Rivas, J. M. (2020). Small Intestinal Bacterial Overgrowth. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK546634/
  41. Sweetnich, J. (2023, February 22). How Stress Affects Our Gut Health. Rupa Health. https://www.rupahealth.com/post/how-stress-affects-our-gut-health
  42. Takakura, W., & Pimentel, M. (2020). Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome – An Update. Frontiers in Psychiatry, 11. https://doi.org/10.3389/fpsyt.2020.00664
  43. Teeter, L. A. (2023, April 25). Complementary and Integrative Medicine for The Treatment of Autoimmune Diseases. Rupa Health. https://www.rupahealth.com/post/complementary-and-integrative-medicine-for-the-treatment-of-autoimmune-diseases
  44. Weinberg, J. L. (2022, June 6). How To Treat Gastroparesis Without Medication. Rupa Health. https://www.rupahealth.com/post/natural-remedies-for-gastroparesis
  45. Weinberg, J. L. (2022, September 7). An Integrative Medicine Approach to Hypothyroidism. Rupa Health. https://www.rupahealth.com/post/understanding-hypothyroidism-and-how-to-treat-it-naturally
  46. Wylie, M. R., & Merrell, D. S. (2022). The Antimicrobial Potential of the Neem Tree Azadirachta indica. Frontiers in Pharmacology, 13. https://doi.org/10.3389/fphar.2022.891535
Order from 30+ labs in 20 seconds (DUTCH, Mosaic, Genova & More!)
We make ordering quick and painless — and best of all, it's free for practitioners.

Latest Articles

View more on Protocols
Subscribe to the magazine for expert-written articles straight to your inbox
Join the thousands of savvy readers who get root cause medicine articles written by doctors in their inbox every week!
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Subscribe to the Magazine for free to keep reading!
Subscribe for free to keep reading, If you are already subscribed, enter your email address to log back in.
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Are you a healthcare practitioner?
Thanks for subscribing!
Oops! Something went wrong while submitting the form.
Trusted Source
Rupa Health
Medical Education Platform
Visit Source
Visit Source
American Cancer Society
Foundation for Cancer Research
Visit Source
Visit Source
National Library of Medicine
Government Authority
Visit Source
Visit Source
Journal of The American College of Radiology
Peer Reviewed Journal
Visit Source
Visit Source
National Cancer Institute
Government Authority
Visit Source
Visit Source
World Health Organization (WHO)
Government Authority
Visit Source
Visit Source
The Journal of Pediatrics
Peer Reviewed Journal
Visit Source
Visit Source
CDC
Government Authority
Visit Source
Visit Source
Office of Dietary Supplements
Government Authority
Visit Source
Visit Source
National Heart Lung and Blood Institute
Government Authority
Visit Source
Visit Source
National Institutes of Health
Government Authority
Visit Source
Visit Source
Clinical Infectious Diseases
Peer Reviewed Journal
Visit Source
Visit Source
Brain
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of Rheumatology
Peer Reviewed Journal
Visit Source
Visit Source
Journal of the National Cancer Institute (JNCI)
Peer Reviewed Journal
Visit Source
Visit Source
Journal of Cardiovascular Magnetic Resonance
Peer Reviewed Journal
Visit Source
Visit Source
Hepatology
Peer Reviewed Journal
Visit Source
Visit Source
The American Journal of Clinical Nutrition
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of Bone and Joint Surgery
Peer Reviewed Journal
Visit Source
Visit Source
Kidney International
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of Allergy and Clinical Immunology
Peer Reviewed Journal
Visit Source
Visit Source
Annals of Surgery
Peer Reviewed Journal
Visit Source
Visit Source
Chest
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of Neurology, Neurosurgery & Psychiatry
Peer Reviewed Journal
Visit Source
Visit Source
Blood
Peer Reviewed Journal
Visit Source
Visit Source
Gastroenterology
Peer Reviewed Journal
Visit Source
Visit Source
The American Journal of Respiratory and Critical Care Medicine
Peer Reviewed Journal
Visit Source
Visit Source
The American Journal of Psychiatry
Peer Reviewed Journal
Visit Source
Visit Source
Diabetes Care
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of the American College of Cardiology (JACC)
Peer Reviewed Journal
Visit Source
Visit Source
The Journal of Clinical Oncology (JCO)
Peer Reviewed Journal
Visit Source
Visit Source
Journal of Clinical Investigation (JCI)
Peer Reviewed Journal
Visit Source
Visit Source
Circulation
Peer Reviewed Journal
Visit Source
Visit Source
JAMA Internal Medicine
Peer Reviewed Journal
Visit Source
Visit Source
PLOS Medicine
Peer Reviewed Journal
Visit Source
Visit Source
Annals of Internal Medicine
Peer Reviewed Journal
Visit Source
Visit Source
Nature Medicine
Peer Reviewed Journal
Visit Source
Visit Source
The BMJ (British Medical Journal)
Peer Reviewed Journal
Visit Source
Visit Source
The Lancet
Peer Reviewed Journal
Visit Source
Visit Source
Journal of the American Medical Association (JAMA)
Peer Reviewed Journal
Visit Source
Visit Source
Pubmed
Comprehensive biomedical database
Visit Source
Visit Source
Harvard
Educational/Medical Institution
Visit Source
Visit Source
Cleveland Clinic
Educational/Medical Institution
Visit Source
Visit Source
Mayo Clinic
Educational/Medical Institution
Visit Source
Visit Source
The New England Journal of Medicine (NEJM)
Peer Reviewed Journal
Visit Source
Visit Source
Johns Hopkins
Educational/Medical Institution
Visit Source
Visit Source

Hey practitioners! 👋 Join Dr. Chris Magryta and Dr. Erik Lundquist for a comprehensive 6-week course on evaluating functional medicine labs from two perspectives: adult and pediatric. In this course, you’ll explore the convergence of lab results across different diseases and age groups, understanding how human lab values vary on a continuum influenced by age, genetics, and time. Register Here! Register Here.

Hey practitioners! 👋 Join Dr. Terry Wahls for a 3-week bootcamp on integrating functional medicine into conventional practice, focusing on complex cases like Multiple Sclerosis. Learn to analyze labs through a functional lens, perform nutrition-focused physical exams, and develop personalized care strategies. Register Here.